Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.55
SPPI's Cash to Debt is ranked higher than
59% of the 1244 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. SPPI: 1.55 )
SPPI' s 10-Year Cash to Debt Range
Min: 0.2   Max: 17918
Current: 1.55

0.2
17918
Equity to Asset 0.50
SPPI's Equity to Asset is ranked higher than
63% of the 933 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. SPPI: 0.50 )
SPPI' s 10-Year Equity to Asset Range
Min: 0.2   Max: 0.95
Current: 0.5

0.2
0.95
F-Score: 4
Z-Score: 0.69
M-Score: -3.32
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -20.65
SPPI's Operating margin (%) is ranked higher than
79% of the 1022 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. SPPI: -20.65 )
SPPI' s 10-Year Operating margin (%) Range
Min: -68658.54   Max: 30.17
Current: -20.65

-68658.54
30.17
Net-margin (%) -46.53
SPPI's Net-margin (%) is ranked higher than
76% of the 1022 Companies
in the Global Biotechnology industry.

( Industry Median: -78.55 vs. SPPI: -46.53 )
SPPI' s 10-Year Net-margin (%) Range
Min: -67890.24   Max: 35.19
Current: -46.53

-67890.24
35.19
ROE (%) -29.92
SPPI's ROE (%) is ranked higher than
75% of the 1141 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. SPPI: -29.92 )
SPPI' s 10-Year ROE (%) Range
Min: -888.98   Max: 39.19
Current: -29.92

-888.98
39.19
ROA (%) -17.02
SPPI's ROA (%) is ranked higher than
78% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: -27.84 vs. SPPI: -17.02 )
SPPI' s 10-Year ROA (%) Range
Min: -321.68   Max: 23.98
Current: -17.02

-321.68
23.98
ROC (Joel Greenblatt) (%) -613.45
SPPI's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 1220 Companies
in the Global Biotechnology industry.

( Industry Median: -415.02 vs. SPPI: -613.45 )
SPPI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -5547.35   Max: 3089.46
Current: -613.45

-5547.35
3089.46
Revenue Growth (3Y)(%) 19.70
SPPI's Revenue Growth (3Y)(%) is ranked higher than
90% of the 727 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. SPPI: 19.70 )
SPPI' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 211.9
Current: 19.7

0
211.9
EBITDA Growth (3Y)(%) -34.00
SPPI's EBITDA Growth (3Y)(%) is ranked higher than
59% of the 716 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. SPPI: -34.00 )
SPPI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -70.9   Max: 108.9
Current: -34

-70.9
108.9
EPS Growth (3Y)(%) 2.40
SPPI's EPS Growth (3Y)(%) is ranked higher than
82% of the 732 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. SPPI: 2.40 )
SPPI' s 10-Year EPS Growth (3Y)(%) Range
Min: -71.4   Max: 131.1
Current: 2.4

-71.4
131.1
» SPPI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

SPPI Guru Trades in Q4 2013

Paul Tudor Jones 13,000 sh (New)
Jim Simons 69,517 sh (+478.49%)
» More
Q1 2014

SPPI Guru Trades in Q1 2014

Jim Simons 171,307 sh (+146.42%)
Paul Tudor Jones Sold Out
» More
Q2 2014

SPPI Guru Trades in Q2 2014

Jim Simons 185,917 sh (+8.53%)
» More
Q3 2014

SPPI Guru Trades in Q3 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with SPPI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Burbank 2012-12-31 Sold Out 0.13%$10.64 - $12.31 $ 6.97-39%0
Joel Greenblatt 2012-12-31 Sold Out 0.02%$10.64 - $12.31 $ 6.97-39%0
Joel Greenblatt 2012-12-31 Sold Out 0.02%$10.64 - $12.31 $ 6.97-39%0
John Burbank 2012-09-30 New Buy0.13%$11.6 - $17.05 $ 6.97-50%250000
Joel Greenblatt 2012-09-30 New Buy0.02%$11.6 - $17.05 $ 6.97-50%19901
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.79
SPPI's P/B is ranked higher than
92% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 6.37 vs. SPPI: 1.79 )
SPPI' s 10-Year P/B Range
Min: 0.63   Max: 5.23
Current: 1.79

0.63
5.23
P/S 2.53
SPPI's P/S is ranked higher than
94% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 29.14 vs. SPPI: 2.53 )
SPPI' s 10-Year P/S Range
Min: 1.07   Max: 650
Current: 2.53

1.07
650
EV-to-EBIT -11.14
SPPI's EV-to-EBIT is ranked lower than
52% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SPPI: -11.14 )
SPPI' s 10-Year EV-to-EBIT Range
Min: -26.9   Max: 63.5
Current: -11.14

-26.9
63.5
Current Ratio 2.05
SPPI's Current Ratio is ranked higher than
60% of the 1237 Companies
in the Global Biotechnology industry.

( Industry Median: 4.71 vs. SPPI: 2.05 )
SPPI' s 10-Year Current Ratio Range
Min: 0.56   Max: 16.82
Current: 2.05

0.56
16.82
Quick Ratio 1.96
SPPI's Quick Ratio is ranked higher than
62% of the 1237 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. SPPI: 1.96 )
SPPI' s 10-Year Quick Ratio Range
Min: 0.56   Max: 16.8
Current: 1.96

0.56
16.8

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 697.00
SPPI's Price/Tangible Book is ranked higher than
61% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. SPPI: 697.00 )
SPPI' s 10-Year Price/Tangible Book Range
Min: 0.66   Max: 825
Current: 697

0.66
825
Price/DCF (Projected) 1.43
SPPI's Price/DCF (Projected) is ranked higher than
98% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. SPPI: 1.43 )
SPPI' s 10-Year Price/DCF (Projected) Range
Min: 1.44   Max: 9.32
Current: 1.43

1.44
9.32
Price/Median PS Value 0.56
SPPI's Price/Median PS Value is ranked higher than
93% of the 1336 Companies
in the Global Biotechnology industry.

( Industry Median: 2.24 vs. SPPI: 0.56 )
SPPI' s 10-Year Price/Median PS Value Range
Min: 0.13   Max: 2276.79
Current: 0.56

0.13
2276.79
Earnings Yield (Greenblatt) -9.00
SPPI's Earnings Yield (Greenblatt) is ranked higher than
69% of the 1217 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. SPPI: -9.00 )
SPPI' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.6   Max: 2183.8
Current: -9

1.6
2183.8

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NTR.Germany,
Spectrum Pharmaceuticals Inc was incorporated in Colorado in December 1987 as Americus Funding Corporation and reincorporated in Delaware in June 1997. The Company changed its corporate name in August 1996 to NeoTherapeutics, Inc., and to Spectrum Pharmaceuticals, Inc in December 2002. The Company and its wholly-owned subsidiaries is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology. The Company market four oncology drugs: FUSILEV injection, ZEVALIN injection, FOLOTYN injection, and MARQIBO injection. Its product portfolio consisting of both commercial stage and development stage products that address various cancer types. FUSILEV, a novel folate analog formulation and the pharmacologically active isomer (the levo-isomer) of the racemic compound, calcium leucovorin. FOLOTYN, a folate analogue metabolic inhibitor, was discovered by Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute and developed by Allos Therapeutics, Inc. ZEVALIN injection for intravenous use is a prescription medication that is part of a three step treatment regimen consisting of: two treatments of rituximab and one treatment of Yttrium-90 (Y-90) ZEVALIN. MARQIBO is a novel, sphingomyelin/cholesterol liposome-encapsulated formulation of the FDA-approved anticancer drug vincristine. The Company markets and sells its drugs through a direct sales force in the U.S., and through distributors in Europe and Japan. The Company competes with Astra Zeneca PLC, Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Co., Novartis AG, Genentech, Inc. (Roche), Bristol-Myers Squibb Company, GlaxoSmithKline, Biogen-IDEC Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc. (Astellas Pharma), Cephalon, Inc. (Teva Pharmaceuticals), Sanofi-Aventis, Inc., Pfizer, Inc., Genta Incorporated, Merck, Celgene Corporation, BiPar Sciences, Inc., Genzyme Corporation, Shire Pharmaceuticals, Abbott Laboratories, Poniard Pharmaceuticals, Inc., and Johnson & Johnson. The development, production and marketing of its proprietary and generic drug and biologic products are subject to regulation for safety, efficacy and quality by numerous governmental authorities in the U.S. and other countries.
» More Articles for SPPI

Headlines

Articles On GuruFocus.com
http://seekingalpha. Aug 14 2012 
Spectrum: Allos Acquisition Means Huge Upside Potential May 04 2012 
5 Stocks Exceeding Expectations In 2012 Mar 31 2012 
Was Gilead's Acquisition of Pharmasset a Dose of Bad Medicine? Mar 05 2012 
Spectrum Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
Weekly CFO Buys Highlight: CNYD, PRWT, ANCB, SPPI, SPAX Jan 30 2011 
Weekly CFO Buys Highlight: FUL, SPPI, GRF, BPAX Jan 24 2011 
Weekly Top Insider Buys: NPBC, FUL, GAM, SHLM, SPPI Jan 23 2011 
Spectrum Pharmaceuticals Inc. (SPPI) CFO Brett L Scott buys 4,000 Shares Jan 21 2011 
Spectrum Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2010 

More From Other Websites
Ligand Partner Spectrum Pharmaceuticals Announces Submission of New Drug Application for... Dec 26 2014
Spectrum submits blood-cancer drug for FDA approval Dec 26 2014
Spectrum Pharmaceuticals Files a New Drug Application with the FDA for Captisol-Enabled™... Dec 26 2014
Spectrum Pharmaceuticals Files a New Drug Application with the FDA for Captisol-Enabled™... Dec 26 2014
7:00 am Spectrum Pharma files a new drug application with the FDA for captisol-enabled Melphalan Dec 26 2014
Market's most shorted stocks Dec 10 2014
Spectrum Pharmaceuticals Highlights 11 Abstracts at the 56th Annual Meeting of the American Society... Dec 05 2014
Spectrum Pharmaceuticals Highlights 11 Abstracts at the 56th Annual Meeting of the American Society... Dec 05 2014
SPECTRUM PHARMACEUTICALS INC Financials Nov 18 2014
Biotech Stock Mailbag: Spectrum, Intercept, Orexigen, Amarin, MannKind Nov 14 2014
10-Q for Spectrum Pharmaceuticals, Inc. Nov 12 2014
Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2014 Global London Healthcare... Nov 12 2014
Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2014 Global London Healthcare... Nov 12 2014
Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2014 Global London Healthcare... Nov 12 2014
SPECTRUM PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report Nov 10 2014
Spectrum Pharma posts 3Q loss Nov 07 2014
Spectrum Pharma posts 3Q loss Nov 07 2014
Spectrum Pharmaceuticals Reports Strong Product Sales for the Third Quarter 2014; Sales of $47.9... Nov 06 2014
Spectrum Pharmaceuticals Inc Earnings Call scheduled for 4:30 pm ET today Nov 06 2014
SPECTRUM PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 06 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK